Scientists at the Babraham Institute have identified a new signalling process in the heart. This discovery will help scientists and doctors to understand the complex biochemistry that causes the abnormal thickening of the heart muscle – called hypertrophy – in response to conditions such as high blood pressure and coronary heart disease. As hypertrophy can lead to debilitating heart failure, and diseases of the cardiovascular system (heart and blood vessels) are responsible for about one third of all deaths in the western world, understanding the cellular signals behind this aberrant growth of the heart is vitally important. This discovery, reported in the scientific journal Molecular Cell, potentially paves the way for innovative treatments to tackle cardiac hypertrophy.
“Until recently, it was considered that disease-induced changes in the shape of calcium increases in heart cells switched on genes that controlled hypertrophic growth,” explained Dr Llewelyn Roderick, leading the research team. “We have found, however, that localised calcium increases in the cell nucleus, which are quite separate from the large increases in cellular calcium responsible for general contraction of heart cells, activate hypertrophic genes. In this way, cardiac myocytes control their own destiny; it’s just a matter of location, location, location.”
Funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and The British Heart Foundation, the combined use of sophisticated imaging and genetic manipulation techniques has revealed that the changes in calcium signalling that result in hypertrophy occur in the nucleus of the cell. These nuclear calcium signals are ‘special’ and distinct from the electrically-evoked calcium signals controlling the regular contraction of the heart. The nuclear calcium signals are generated following the opening of inositol 1,4,5-trisphosphate receptor calcium channels (IP3Rs), which surround the nucleus. These channels open when they sense an increase in the cellular levels of a chemical messenger called inositol 1,4,5-trisphosphate, IP3, which is produced after the binding of a hormone called endothelin to its receptors on the surface of cardiac myocytes (heart muscle cells). Significantly, a molecule called NFAT, known to regulate genes involved in pathological hypertrophy, was activated by these IP3-mediated increases in nuclear calcium and not as previously thought by the calcium signals associated with contraction.
In this study, the authors found stimuli other than endothelin also induced hypertrophy via the IP3-calcium-NFAT pathway. They showed that these stimuli, such as adrenalin (the fight or flight hormone), act by causing endothelin to be secreted from cardiac myocytes. This secreted endothelin then induces IP3-dependent calcium release in the same cells from which the endothelin was originally secreted. As endothelin levels are higher in patients with heart disease and inhibition of endothelin signalling has been reported to have certain beneficial effects, this finding has significant relevance to human disease.
“We have uncovered a new cellular signalling loop that is key to regulating many forms of cardiac hypertrophy, said Dr Roderick. “This discovery has great clinical significance, supporting the notion that the endothelin pathway is a good target for pharmacological intervention and that intervening in inositol 1,4,5-trisphosphate signalling would be a suitable target for the development of future therapies. “
Professor Jeremy Pearson, Associate Medical Director at the British Heart Foundation commented, "Levels of calcium inside heart muscle cells must rapidly change to allow them to contract and relax with every heart beat. However, changes in calcium can also alter heart muscle cell structure in response to injury, such as after a heart attack, and potentially lead to hypertrophy and heart failure. It is vital to understand how hypertrophy develops and until now, researchers have not understood how these two different actions of calcium inside the cell are separately controlled.”
“This excellent piece of work from the Babraham Institute has used cutting-edge imaging techniques to show that the location in the cell where these calcium changes take place is crucial. They have shown for the first time that the calcium changes leading to hypertrophy only take place in the nucleus of the cell. They have also discovered the molecular pathways which control this rise in calcium in the nucleus. This is vitally important research to understand how cardiac hypertrophy develops and the discovery of these pathways may provide clues to guide the development of new drugs to prevent this condition."
Dr Claire Cockcroft
Head, External Relations
Tel: +44 (0)1223 496260
Mobile: +44 (0)7786 335978
Dr Llewelyn Roderick
Tel: 01223 496489
The Babraham Institute
Babraham Research Campus
Cambridge CB22 3AT
Higazi DR, Fearnley CJ, Drawnel FM, Talasila A, Corps EM, Ritter O, McDonald F, Mikoshiba K, Bootman MD, Roderick HL (2009)
Endothelin-1-stimulated InsP3-induced Ca2+ release is a nexus for hypertrophic signaling in cardiac myocytes.
Molecular Cell 33 472-482
Notes to Editors:
The Babraham Institute is a charitable organisation devoted to biomedical research and is an institute of the Biotechnology and Biological Sciences Research Council (BBSRC). The Institute’s research is focused on understanding the biological events that underlie the normal functions of cells and on how their failure or abnormality may lead to disease. As such, Institute scientists are striving to find cures for conditions where there is currently no treatment or where the existing treatment is not fully effective or causes serious side effects. The latest technologies are being used to study the basis of conditions such as neurodegenerative disorders, birth defects, cancer and diseases of the immune and cardiovascular systems. With a strategic focus on ‘healthy ageing’, novel approaches for tackling chronic diseases and public health concerns like obesity are being discovered. The Institute’s innovative research is commercialised through Babraham Bioscience Technologies (BBT) Ltd, which also manages Babraham’s vibrant Bioincubator on the Babraham Research Campus, six miles south-east of Cambridge. Website: www.babraham.co.uk
The British Heart Foundation (BHF) is the nation's heart charity, dedicated to saving lives through pioneering research, patient care, campaigning for change and by providing vital information. But we urgently need help. We rely on donations of time and money to continue our life-saving work. Because together we can beat heart disease. For more information visit www.bhf.org.uk
Babraham Institute - Babraham Research Campus - Cambridge - United Kingdom